Opinion|Videos|November 8, 2024
Use of Targeted Agents in Generalized Myasthenia Gravis
Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.
Advertisement
Video content above is prompted by the following:
- In which patients and when do you typically use FcRn inhibitors and complement inhibitors?
- Where do FcRn inhibitors fit in the long-term management of gMG?
- How do you monitor patients with gMG, especially those receiving FcRn or complement inhibitor therapies?
- How do you manage gMG in patients who have inadequate disease control with traditional treatments and those currently on targeted therapies?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
2
SKY-0515 Demonstrates Dose-Dependent Reductions in Mutant Huntingtin Protein in Phase 1 Update
3
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
4
Exploring the Unmet Need for FDA-Approved Therapies in Stuttering: Gerald McGuire, MD
5